The estimated Net Worth of William Ragatz is at least $406 dollars as of 27 January 2020. Mr. Ragatz owns over 16,250 units of Viela Bio stock worth over $406 and over the last 5 years he sold VIE stock worth over $0. In addition, he makes $0 as Vice President - Head of Commercial at Viela Bio.
William has made over 1 trades of the Viela Bio stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 16,250 units of VIE stock worth $84,825 on 27 January 2020.
The largest trade he's ever made was exercising 16,250 units of Viela Bio stock on 27 January 2020 worth over $84,825. On average, William trades about 5,417 units every 0 days since 2020. As of 27 January 2020 he still owns at least 16,250 units of Viela Bio stock.
You can see the complete history of Mr. Ragatz stock trades at the bottom of the page.
William Ragatz serves as Vice President - Head of Commercial of the Company. From February 2017 to January 2019, Mr. Ragatz served as a Director of Marketing for AstraZeneca, our largest stockholder, leading the worldwide commercial strategy for anifrolumab in systemic lupus erythematosus. Prior to joining AstraZeneca, Mr. Ragatz spent 15 years at Boehringer-Ingelheim, a group of C.H. Boehringer Sohn AG & Ko. KG, in roles of increasing responsibility, most recently as Director of Marketing and previously as Director of Operations. Mr. Ragatz received his B.B.A. in Accounting from Iowa State University and M.B.A. from the Fuqua School of Business at Duke University.
William Ragatz is 51, he's been the Vice President - Head of Commercial of Viela Bio since 2019. There are 5 older and 6 younger executives at Viela Bio. The oldest executive at Viela Bio, Inc. is Chris Nolet, 63, who is the Independent Director.
William's mailing address filed with the SEC is C/O VIELA BIO, INC.,, ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG, MD, 20878.
Over the last 5 years, insiders at Viela Bio have traded over $58,712,400 worth of Viela Bio stock and bought 1,261,091 units worth $24,062,867 . The most active insiders traders include Andreas Wicki, Xiaomeng Tong, and Plc Astra Zeneca Uk Ltd Ast.... On average, Viela Bio executives and independent directors trade stock every 41 days with the average trade being worth of $6,348. The most recent stock trade was executed by Aaron Ren on 18 November 2020, trading 2,000 units of VIE stock currently worth $5,680.
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Viela Bio executives and other stock owners filed with the SEC include: